Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

Emilie M. J. van Brummelen, Sanne Huijberts, Carla van Herpen, Ingrid Desar, Frans Opdam, Robin van Geel, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin Huitema, Jos Beijnen, Rene Bernards, Jan Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)290-e545
Number of pages6
JournalOncologist
Volume26
Issue number4
Early online date29 Dec 2020
DOIs
Publication statusPublished - Apr 2021

Keywords

  • Afatinib
  • Selumetinib
  • KRAS
  • Colorectal cancer
  • Non&#8208
  • small cell lung cancer
  • Pancreatic cancer
  • MEK INHIBITION

Cite this